Medical Supply Chain Resiliency Act
HB2213, the Medical Supply Chain Resiliency Act, would authorize the President to negotiate and enter into trade agreements with foreign countries to eliminate or reduce duties, quotas, and other import restrictions on medical goods. The bill is aimed at strengthening the U.S. medical supply chain by encouraging trade with “trusted trade partners” that maintain open trade during emergencies, protect intellectual property, support regulatory cooperation, and adhere to transparent, nondiscriminatory laws and good regulatory practices.
The bill’s findings cite the COVID-19 pandemic as evidence that the United States needs more diversified and reliable sources for pharmaceuticals, medical devices, and related inputs. It directs the executive branch to consider factors such as a country’s willingness to enter an agreement, its record on trade openness during public health emergencies, its compliance with existing trade commitments, and its protection of intellectual property and regulatory standards. The bill also allows agreements to include streamlined customs and regulatory procedures, expanded procurement access, research and development cooperation, and exemptions from certain trade-restrictive measures during public health emergencies.
HB2213 would affect federal trade law by creating a new framework for “trusted trade partner agreements” specific to medical goods. It gives the President authority to modify duties and other import treatment to implement such agreements, but only after consultation, reporting, and a congressional review process. The bill requires advance notice to Congress, periodic status reports, and a mechanism for Congress to disapprove an agreement before it takes effect. It also establishes ongoing monitoring and enforcement procedures if a partner fails to comply, including possible suspension of benefits or reimposition of restrictions.
The general sentiment reflected in the bill text is strongly supportive of supply chain resilience, public health preparedness, and national security. The bill is framed as a response to pandemic-era shortages and overreliance on a small number of foreign suppliers, and it emphasizes cooperation with reliable allies and trade partners. No committee transcript or vote record was provided, so there is no recorded floor or committee debate to indicate broader political sentiment beyond the bill’s bipartisan introduction by Representatives Malliotakis and Schneider.
The main points of potential contention are likely to involve trade policy, executive authority, and the balance between openness and protection. The bill would give the President significant discretion to negotiate and implement medical-goods trade agreements, though Congress retains a review-and-disapproval role. Other possible concerns include the emphasis on intellectual property protections, regulatory harmonization, and the possibility that trade benefits could be conditioned on foreign governments’ policy choices. Supporters are likely to focus on resilience and emergency preparedness, while skeptics may question whether the framework could constrain domestic industrial policy or complicate existing trade relationships.
The bill would create a new federal authority for negotiating medical-goods trade agreements and would add a specialized statutory framework governing duties, import restrictions, congressional consultation, reporting, review, and enforcement for those agreements. It would not directly amend the Federal Food, Drug, and Cosmetic Act, but it defines medical devices and pharmaceutical goods by reference to that law and would affect how trade policy interacts with imports of drugs, devices, and inputs. If enacted and used, it could change tariff treatment and trade conditions for medical goods and influence supply chains, procurement access, and regulatory cooperation with partner countries.
The bill’s tone is generally positive and bipartisan, with an emphasis on resilience, national security, and public health preparedness. Its findings and purposes present the measure as a response to COVID-19-era shortages and supply chain vulnerabilities, and the introduction by members of both parties suggests cross-party appeal. No votes or committee discussion were provided, so there is no recorded opposition or support beyond the bill’s text and sponsorship.
Likely areas of contention include the scope of presidential authority to negotiate and implement trade agreements, the degree of congressional oversight, and whether the bill could favor certain foreign suppliers or trade partners over domestic production. The bill also raises policy questions about intellectual property protections, regulatory harmonization, and the use of trade agreements to shape public-health supply chains. Supporters are likely to prioritize diversification and emergency readiness, while critics may worry about reduced flexibility for domestic manufacturing policy or the possibility that trade concessions could be too broad.